Clinical experience with nonstandard doses of interferon alfa-2b and ribavirin in the treatment of chronic hepatitis C infection: A retrospective analysis

Current Therapeutic Research - Clinical and Experimental

Volumn 66, Issue 5, 2005, Pages 433-450

  Hare, C Bradley ^a   Loveland, Jacqueline J ^b   Chu, Alice ^b   Morris, Jonathan A ^b   Gotz, Vincent ^b   Klaskala, Winslow ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ProSanos Corporation   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

Dosing; Hepatitis C; Interferon alfa 2b and ribavirin; Outcomes; Pegylated interferon; Ribavirin

Indexed keywords

ALPHA2B INTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REGIMEN; FATIGUE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; VIRUS LOAD;

EID: 30344485390     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2005.10.005     Document Type: Article

References (33)

1. National Institutes of Health Consensus Development Conference Statement Management of Hepatitis C: 2002 - June 10-12, 2002 Hepatology 36 Suppl 1 2002 S3 S20
2. Centers for Disease Control and Prevention Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease MMWR Recomm Rep. 47 1998 1 39
3. Alter M.J. Epidemiology of hepatitis C Hepatology 26 Suppl 1 1997 62S 65S
4. Alter M.J. Epidemiology of hepatitis C and lookback Hematology (Am Soc Hematol Educ Program) 1999 418
5. Alter M.J., Kruszon-Moran D., and Nainan O.V. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 N Engl J Med. 341 1999 556 562
6. European Association for the Study of the Liver (EASL) EASL International Consensus Conference on Hepatitis C February 26-28, 1999; Paris, France. Consensus statement J Hepatol. 30 1999 956 961
7. Culver D.H., Alter M.J., Mullan R.J., and Margolis H.S. Evaluation of the effectiveness of targeted lookback for HCV infection in the United States-interim results Transfusion 40 2000 1176 1181
8. Seeff L.B., and Hoofnagle J.H. National Institutes of Health Consensus Development Conference: Management of hepatitis C: 2002 Hepatology 36 Suppl 1 2002 S1 S2
9. Davis G.L. Current treatment for chronic hepatitis C Rev Gastroenterol Disord. 1 2001 59 72
10. Poynard T., Marcellin P., Lee S.S. International Hepatitis Interventional Therapy Group (IHIT)^ Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus Lancet 352 1998 1426 1432
11. Manns M.P., McHutchison J.G., and Gordon S.C. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomisedtrial Lancet 358 2001 958 965
12. Fried M.W., Shiffman M.L., and Reddy K.R. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med. 347 2002 975 982
13. Zeuzem S., Feinman S.V., and Rasenack J. Peginterferon alfa-2a in patients with chronic hepatitis C N Engl J Med. 343 2000 1666 1672
14. Lindsay K.L., Trepo C., Heintges T. Hepatitis Interventional Therapy Group A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C Hepatology 34 2001 395 403
15. Heathcote E.J., Shiffman M.L., and Cooksley W.G. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis N Engl J Med. 343 2000 1673 1680
16. McHutchison J.G., Manns M., Patel K. International Hepatitis Interventional Therapy Group Adherence to combination therapy enhances sustained response in genotype-l-infected patients with chronic hepatitis C Gastroenterology 123 2002 1061 1069
17. Reichard O., Andersson J., Schvarcz R., and Weiland O. Ribavirin treatment for chronic hepatitis C Lancet 337 1991 1058 1061
18. Di Bisceglie A.M., Shindo M., and Fong T.L. A pilot study of ribavirin therapy for chronic hepatitis C Hepatology 16 1992 649 654
19. Dusheiko G., Main J., and Thomas H. Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study J Hepatol. 25 1996 591 598
20. Bodenheimer H.C. Jr, Lindsay K.L., and Davis G.L. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial Hepatology 26 1997 473 477
21. Reichard O., Norkrans G., Fryden A. Swedish Study Group Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C Lancet 351 1998 83 87
22. McHutchison J.G., Gordon S.C., Schiff E.R. Hepatitis Interventional Therapy Group Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C N Engl J Med. 339 1998 1485 1492
23. Reddy K.R., Wright T.L., and Pockros P.J. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C Hepatology 33 2001 433 438
24. PEG-Intern (pegylated interferon alfa-2b) 2001 Schering Corporation Somerville, NJ
25. PEGASYS (pegylated interferon alfa-2a) 2002 HoffmannLa Roche Inc Nutley, NJ
26. Tam R.C., Ramasamy K., and Bard J. The ribavirin analog ICN 17261 demonstrates reduced toxicity and antiviral effects with retention of both immunomodulatory activity and reductionof hepatitis-induced serum alanine aminotransferase levels Antimicrob Agents Chemother 44 2000 1276 1283
27. Rebetol (ribavirin) 2001 Schering Corporation Somerville, NJ
28. Roferon-A (interferon alfa-2a, recombinant) 2001 HoffmannLa Roche, Inc Nutley, NJ
29. Rebetron (combination therapy containing interferon alfa-2b, recombinant, and ribavirin) 2002 Schering Corporation Somerville, NJ
30. (Suppl) Reddy S.I., and Ukomadu C. Viral hepatitis and hepatocellular carcinoma in African Americans Cancer Epidemiol Biomarkers Prev. 12 2003 248s 251s
31. Sugimoto K., Stadanlick J., and Ikeda F. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response Hepatology 37 2003 590 599
32. Fried M.W. Side effects of therapy of hepatitis C and their management Hepatology 36 Suppl 1 2002 S237 S244
33. Hadziyannis S., Sette H. Jr, Morgan T.R. PEGASYS International Study Group Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose Ann Intern Med. 140 2004 346 355